Compare skin treatments
Polynucleotides for Acne Scarring: What the Studies So Far Show
Information to help you prepare questions. Treatment suitability, risks and aftercare are assessed individually with the clinic.

Short answer: polynucleotide injections have been studied for atrophic (indented) acne scars, and the early results are encouraging but limited. The best-known data come from small trials, several of them without a control group and many connected to one product line. They do not show that polynucleotides remove acne scars, and they do not show how long any improvement lasts. Whether they are worth discussing for your scars depends on the type and depth of the scarring, which a practitioner needs to see in person.
Evidence as of 9 November 2026. This is general information, not medical advice or a diagnosis.
What "acne scarring" means here
Acne can leave atrophic scars, which are indented marks such as ice-pick, boxcar and rolling scars. It can also leave raised scars, or flat marks that are red or dark and fade over time. The studies below concern atrophic scars. They do not cover red or brown marks, or raised scars.
The NHS says to see a GP if acne is causing scarring or self-treatment is not working, and that a GP may refer you to a dermatologist. It advises against picking or squeezing spots because this can lead to scars (NHS: acne treatment, last reviewed 22 September 2026). If you still have active acne, it is sensible to get that under control first. A scar treatment cannot stop new scars forming.
What polynucleotides are, in one paragraph
Polynucleotides are DNA-derived molecules; those used in aesthetic medicine are commonly made from purified salmon or trout DNA. A 2025 systematic review describes them as having regenerative properties, first used in wound healing, and notes that research in aesthetic medicine has concentrated on skin rejuvenation rather than scars (Lampridou et al., Journal of Cosmetic Dermatology, 2025). Our overview is on the polynucleotide treatment page.
What the studies show
The table lists the research found for acne scars specifically. Sample sizes are small throughout.
| Study | Design | Who and what | What was reported | Main limit |
|---|---|---|---|---|
| Araco and Araco, Aesthetic Surgery Journal, 2021 | Randomised, double-blind, saline-controlled | 20 women aged 30–50 with Goodman grade 3–4 atrophic acne scars; polynucleotide (PN-HPT) versus saline | Only the polynucleotide group improved significantly from baseline at 1 and 3 months | Just 20 people; short follow-up; abstract gives no between-group numbers |
| Bartoletti et al., Clinical, Cosmetic and Investigational Dermatology, 2026 | Single-arm real-world cohort, no control group | 30 adults aged 20–60 with grade 3–4 atrophic acne scars; polynucleotide (PN HPT) combined with hyaluronic acid at baseline and weeks 2, 4 and 6 | Blinded Goodman-Baron scores fell 18.8% at 3 months and 22.1% at 6 months; mean scar area fell from 106.6 to 93.1 at 6 months; 25 of 30 gave a positive rating on a global aesthetic improvement scale; grade did not improve in 30% at 6 months | No comparison group; hyaluronic acid was given too, so the effect cannot be credited to polynucleotides alone; the product maker paid the publication charges |
| Postepy Dermatologii i Alergologii, 2026 | Randomised comparison | 100 people with atrophic acne scars; CO₂ laser alone versus laser plus a topical polynucleotide and exosome-mimetic nanovesicle product | Scar score reduction of 47.3% versus 35.9% at 3 months | The polynucleotide was applied topically and combined with another novel ingredient, so it does not test polynucleotide injections |
Points worth noticing:
- The one controlled injection trial is very small. Twenty people is too few to judge how often it works, for whom, or how long it lasts. The authors called for larger and longer studies.
- The larger cohort had no comparison group and used a combination product. Scars can also change over time without treatment, and hyaluronic acid can itself affect how skin looks. A 22% average drop in score is a modest change, and nearly a third of participants stayed in the same grade at six months.
- Industry links are common. The 2026 cohort used a product made by Mastelli, which paid the publication charges, and two of its authors have received research grants from the company. The Korean survey below was funded by PharmaResearch, and its lead author sits on that company's advisory board. The CO₂ laser trial reported no external funding. The 2021 trial's full text is paywalled, so we could not read its funding statement. Industry links do not make findings wrong, but they are why independent trials matter.
- Side effects in the injection cohort were local. In the 2026 cohort, clinicians recorded 10 adverse events across 122 procedures, nine mild and one moderate, limited to haematoma (a small collection of blood), swelling and bruising, with no serious or unexpected events. The 2021 trial abstract does not describe side effects. Studies this small cannot rule out rarer problems.
- More trials are registered. A split-face trial comparing PDRN (polydeoxyribonucleotide, a related DNA-derived ingredient) with hyaluronic acid after subcision for rolling scars is recruiting (ClinicalTrials.gov NCT07547956). A single-arm study of Mastelli's polynucleotide and hyaluronic acid device is listed as completed in July 2025, with no results posted on the registry (NCT05936437).
- A 2026 survey of 501 Korean dermatologists found that 73% used polynucleotides for scars, most often for scar prevention (81.4%) and atrophic scars (74.9%), with injection over three sessions the most common approach. The authors called the findings hypothesis-generating. It describes practice, not results.
A 2026 systematic review of randomised trials of polynucleotides and PDRN across skin rejuvenation, scar prevention and wound healing identified only seven trials (183 participants). It found the evidence limited by small sample sizes, heterogeneous treatment protocols and variable outcome measures, and called for larger, adequately powered trials (Alhussain et al., Cureus, 2026).
What this means for realistic expectations
- Possible, modest improvement is what the studies point to, not removal. UK patient information from the PCDS says there is no topical treatment or oral medication that can effectively treat scarring, and that some people may benefit from physical treatments such as laser, depending on the type of scarring. Acne Support, run by the British Association of Dermatologists, says most scars can be reduced in appearance.
- Scar type probably matters, but this is not proven for polynucleotides. The studies enrolled moderate-to-severe (grade 3–4) atrophic scars, and published data do not tell us who responds best.
- Results are gradual and have been judged at 1 to 6 months. No trial found followed people for long enough to say how long a change lasts.
- Other options exist and may be recommended first or alongside. The PCDS leaflet mentions physical treatments such as laser, and the studies above also involved laser and subcision. We have not compared options here, because the evidence does not support a ranking.
Questions to ask at a consultation
- Are my scars the type the research covered, or would another approach be discussed first?
- What would you expect to be realistic for my scars, and how would we judge progress with photographs?
- How many sessions and what interval are you suggesting, and why? (Studies used different protocols, so this is for your practitioner to confirm.)
- What are the common side effects and who should not have it? Your practitioner will confirm suitability, including any allergies and medicines, before treatment.
- Is it worth waiting for active acne or a recent course of acne medication to settle first?
- What would you do if I did not see enough change?
Next step
If you would like to talk it through, the polynucleotide treatment page explains the treatment and how to book a consultation. For a broader comparison of skin-quality injectables, see polynucleotides vs PRP facial.
Frequently asked questions
Can polynucleotides remove acne scars?
The studies so far do not show removal. Small studies reported modest average improvement in indented acne scars over 3 to 6 months, and some people did not change grade. The research is limited by small samples and, in several cases, no control group.
Which type of acne scar have polynucleotides been studied for?
Atrophic (indented) scars, mainly moderate to severe ones. The published studies do not cover red or dark marks or raised scars.
How many sessions were used in the acne scar studies?
One real-world study gave four injections at baseline and weeks 2, 4 and 6, combined with hyaluronic acid. A survey of Korean dermatologists found three sessions most common. Protocols varied, so your practitioner will confirm what is suitable for you.
Is the evidence independent?
Not entirely. The larger polynucleotide injection study used one maker's product, the maker paid its publication charges and two authors have received grants from it, and a survey of Korean dermatologists was industry-funded. That injection study also had no control group. More independent, controlled trials are needed.
Is treatment for acne scars available on the NHS?
The NHS acne pages advise seeing a GP if acne is causing scarring, and a GP may refer you to a dermatologist. Acne Support guidance says scar treatment is generally not readily available on the NHS, so many people consider private options.
Read about polynucleotide treatment at Progen Aesthetics
Sources and further information
- Bartoletti E et al. 2026, Clin Cosmet Investig Dermatol (DOI 10.2147/CCID.S621545, PMID 42609612, PMC13479430): 30 adults, PN HPT 10 mg/mL with hyaluronic acid (Newest, Mastelli) at baseline and weeks 2, 4, 6; Goodman-Baron scores fell 18.8% at 3 months and 22.12% at 6 months; mean scar area 106.6 to 93.1 at 6 months; "Twenty-five of the 30 cohort subjects who completed follow-up expressed a positive GAIS judgment"; 30% no grade change at 6 months; 10 adverse events in 122 procedures (9 mild, 1 moderate: hematoma, edema, bruising); Mastelli paid article processing charges; two authors received grants from the sponsor.
- Araco and Araco 2021, Aesthet Surg J (PMID 33755110): randomised, double-blind, saline-controlled trial in 20 women aged 30-50 with Goodman grade 3-4 atrophic acne scars; only the PN-HPT group improved significantly at 1 and 3 months.
- Postepy Dermatol Alergol 2026 (PMID 42621380): 100 people, CO2 laser alone vs laser plus topical polynucleotide and exosome-mimetic nanovesicles; ECCA reduction 47.3% vs 35.9% at 3 months.
- Rho NK et al. 2026, J Cosmet Dermatol (PMID 42087414) survey of 501 KAAD dermatologists: 73.0% use PN for scar management; most commonly scar prevention (81.4%) and atrophic scars (74.9%); "Intradermal injection over three sessions was the most common approach"; findings "hypothesis-generating". Funded by PharmaResearch; lead author on PharmaResearch advisory board.
- Alhussain AM et al. Polynucleotides and Polydeoxyribonucleotides for Skin Rejuvenation, Postoperative Scar Prevention, and Wound Healing: A Systematic Review of Randomized Clinical Trials. Cureus 2026 (PMID 42572627): "Seven randomized trials involving 183 participants"; evidence "limited by small sample sizes, heterogeneous treatment protocols, and variable outcome measures"; "Larger, adequately powered randomized trials are needed".
- "Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment." Split-face, Cairo University, estimated 20 participants, status RECRUITING, no results.
- "Clinical Benefits and Safety of Combined Polynucleotides and Hyaluronic Acid - Newest - for Acne Scars Treatment." Single-group, sponsor Mastelli S.r.l, 30 enrolled, status COMPLETED (24 July 2025), no results posted.
- NHS advises seeing a GP if acne is causing scars or self-treatment is not working; a GP may refer to a dermatologist; do not pick or squeeze spots. Page last reviewed 22 September 2026.
- PCDS acne leaflet: "For those that do there is no topical treatment or oral medication that can effectively treat scarring"; "some patients may benefit from physical treatments such as laser or steroid injections, depending on the type of scarring"; laser generally not available on the NHS.
- Acne Support (British Association of Dermatologists): "whilst most scars can be reduced in appearance, treatment for acne scarring is not readily available on the NHS".
- Lampridou S et al. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol 2025 (PMID 39645667, PMC11845969). Abstract: PN "show promise ... due to their regenerative properties, previously used in wound healing"; research "concentrated on skin rejuvenation". Introduction: PN and PDRN "derived from purified DNA of salmon or trout gonads".
More in polynucleotides
Questions people ask next
- Polynucleotides for the Neck and Décolletage: What to Expect
- When Do Polynucleotide Results Show, and How Long Do They Last? What Studies and Clinics Report
- Polynucleotides Under Eyes: What to Expect and Realistic Results
- How Many Polynucleotide Sessions? What Studies Used, What Clinics Say and How Far Apart
Treatment details, suitability and booking: polynucleotides in Bournemouth. All polynucleotides guides
Make an informed next step
Bring your questions
to a consultation.
A guide can help you prepare. Your assessment determines which options are appropriate for you.
Continue reading: Polynucleotides vs PRP Facial: Which Skin Rejuvenation Treatment Is Right for You?